Empowering Technology Transfer Offices

At Oxeltis, we recognize the unique challenges faced by Technology Transfer Offices (TTOs) in transforming promising new biological target discoveries into investable, high-potential clinical lead candidates. Many early-stage programs struggle to mature their assets due to limited access to medicinal chemistry expertise, insufficient knowledge of the drug discovery path and limited data packages for seed funding applications, or the lack of integrated Hit-to-Lead and lead optimization capabilities. These gaps can delay progress, diminish valuation, and hinder the translation of groundbreaking science into commercial opportunities.

Our mission is to bridge this critical gap by providing TTOs with the scientific partnership, agility, and data-driven insights needed to de-risk projects, enhance their attractiveness to investors, and accelerate their journey toward commercialization.

01 — YOUR CHALLENGES

Accelerate Your Projects from Hit to Lead

Glass reaction flask and clamps in the laboratory

Many early-stage programs struggle due to limited access to specialized medicinal chemistry expertise and insufficient knowledge of the drug discovery process. As a result, the data packages supporting seed funding applications are often too thin, which can hinder progress and investment opportunities.

The absence of integrated hit-to-lead and lead optimization capabilities can delay project maturation.

Difficulty in translating groundbreaking science into viable commercial opportunities.

02 — HOW WE HELP

Tailored Solutions for TTOs: From Early Hits to Investor-Ready Leads

Computational Design & Strategic Partnerships

We specialize in maturing early-stage small molecule programs by seamlessly integrating computational design, high-quality synthesis, and biological validation. Through strategic collaborations with Molecular Forecaster (Montreal) for in silico design (CADD, SBDD, LBDD, AI/ML) and Partex.AI Labs for assay development and in vitro screening, we ensure your projects are scientifically robust and investor-ready.

Chemical Expertise, Complex Synthesis & Scale-Up

Our 50% PhD and 50% MSc chemist team delivers high-quality compounds efficiently, enabling you to demonstrate proof-of-concept and secure preliminary data for funding applications. With expertise in complex chemistry, including chiral resolutions and innovative synthetic pathways, our hybrid SFC purification platform supports rapid scale-up (up to 25 g/day), ensuring purity and structural integrity for even the most challenging molecules.

Biological Profiling, DMTA Cycles & IP Protection

We also provide assay design, in vitro screening, and early pharmacology profiling, fully aligned with your chemistry efforts to accelerate DMTA cycles and generate the comprehensive datasets that investors and partners demand. Operating as an extension of your team, we ensure full transparency, data ownership, and alignment with your strategic goals, critical for maintaining IP control and maximizing valuation.

03 — WHY US

De-Risking Your Portfolio for Investors and Partners

For TTOs, time and data are currency. Our integrated approach ensures that your projects mature faster, with stronger preliminary results that enhance their appeal to:

By partnering with Oxeltis, you gain more than a service provider, you gain a scientific ally committed to advancing your portfolio with speed, precision, and strategic insight.

Oxeltis chemist setting up a reaction on a laboratory bench

04 — RELEVANT SERVICES FOR TTO

Services most relevant to Technology Transfer Offices

Fume hoods and rotary evaporator in the Oxeltis laboratory

Turn promising academic hits into high-potential leads through iterative design-make-test cycles, generating the SAR, potency and early property data that licensees and seed investors expect.

Experienced medicinal chemists design and synthesize compounds tailored to your project, expanding the chemical series around your hits to make the asset more attractive for licensing or spin-off creation.

Comprehensive in vitro screening (via Partex.AI Labs) and early ADME profiling, building the robust data package needed to de-risk your project before licensing discussions or funding applications.

Rapid, reliable resynthesis and scale-up of challenging molecules, giving your team enough high-quality material for validation and proof-of-concept studies.

Let’s Build the Future of Your Innovations Together

At Oxeltis, we understand the stakes of early-stage drug discovery. Our 15+ years of expertise in medicinal chemistry and custom synthesis, combined with our collaborative, partnership-driven approach, make us the ideal ally for TTOs aiming to transform scientific promise into commercial reality.

Contact us today to discuss how we can help you mature your projects, secure funding, and accelerate your path to market. Together, we can turn your innovations into the next generation of breakthrough therapies.